LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer ...

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

Siemens Healthineers has tapped the Alzheimer’s disease blood test developer ALZpath for an in vitro diagnostic to ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Treatment with Kisunla was associated with sustained clinical benefits, specifically less symptom worsening and significant amyloid clearance up to 3 years, in early symptomatic Alzheimer’s disease, ...